Any drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
| Member | Definition | Class |
|---|
| alo 2145 | The hydrochloride salt of apraclonidine. | apraclonidine hydrochloride |
| apraclonidine | An imidazoline that is 2-amino 4,5-dihydro-1H-imidazoline in which one of the exocyclic amino hydrogens has been replaced by a 4-amino-2,6-dichlorophenyl group. | apraclonidine |
| bimatoprost | | bimatoprost |
| brinzolamide | | brinzolamide |
| carteolol | | carteolol |
| carteolol hydrochloride | | carteolol hydrochloride |
| dichlorphenamide | A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma. | diclofenamide |
| dipivefrin | The dipivalate ester of (+-)-epinephrine (racepinephrine). A pro-drug of epinephrine, the hydrochloride is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension. | dipivefrin |
| dipivefrin hydrochloride | The hydrochloride salt of dipivefrin. It is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension. | dipivefrin hydrochloride |
| dorzolamide | 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension. | dorzolamide |
| echothiophate iodide | The iodide salt of ecothiopate. An irreversible acetylcholinesterase inhibitor, it is used an ocular antihypertensive in the treatment of open-angle glaucoma, particularly when other drugs have proved inadequate. | ecothiopate iodide |
| ethoxzolamide | A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic. | ethoxzolamide |
| fluprostenol | An organofluorine compound that is racemic prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of its isopropyl ester prodrug, travoprost, are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. The isopropyl ester group of travoprost is hydrolysed to the biologically active free acid by esterases in the cornea. | fluprostenol |
| l 671152 | The hydrochloride salt of dorzolamide. It is used in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension. | dorzolamide hydrochloride |
| latanoprost | A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension. | latanoprost |
| levobunolol | A cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. | levobunolol |
| levobunolol hydrochloride | A hydrochloride obtained by combining equimolar amounts of levobunolol and hydrochloric acid. A non-selective beta-adrenergic antagonist used for treatment of glaucoma. | levobunolol hydrochloride |
| mannitol | The D-enantiomer of mannitol. | D-mannitol |
| metipranolol | 3-(Propan-2-ylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by a 4-acetoxy-2,3,5-trimethylphenoxy group. A non-cardioselective beta-blocker, it is used to lower intra-ocular pressure in the management of open-angle glaucoma. | metipranolol |
| phxa 85 | A prostaglandin Falpha that is an analogue of prostaglandin F2alpha in which the pentyl group has been replaced by 2-phenylethyl and where the the 13,14-double bond has undergone formal hydrogenation. Its isopropyl ester prodrug, latanoprost, is used in the treatment of open-angle glaucoma and ocular hypertension. | latanoprost free acid |
| pilocarpine | The (+)-enantiomer of pilocarpine. | (+)-pilocarpine |
| pindolol | A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol. | pindolol |
| timolol | The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine. | (S)-timolol (anhydrous) |
| timolol maleate | The maleic acid salt of the active (S)-enantiomer of timolol, comprising equimolar amounts of (S)-timolol and maleic acid. | (S)-timolol maleate |
| travoprost | The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol. | travoprost |
| uf 021 | The isopropyl ester of unoprostone. | isopropyl unoprostone |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 43.6486 | 1 | 1 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 10.6822 | 1 | 1 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 16.6564 | 7 | 14 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 27.2798 | 2 | 4 |
| arylsulfatase A | Homo sapiens (human) | Potency | 1.3310 | 1 | 2 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 14.5810 | 1 | 1 |
| Ataxin-2 | Homo sapiens (human) | Potency | 29.8493 | 1 | 2 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 10.9971 | 1 | 4 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 26.6782 | 2 | 3 |
| beta-2 adrenergic receptor | Homo sapiens (human) | Potency | 9.4448 | 3 | 4 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 79.4328 | 2 | 2 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 0.7079 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 48.1895 | 2 | 3 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 23.7531 | 1 | 2 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 17.1152 | 2 | 5 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 1.2589 | 1 | 1 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 2.0191 | 1 | 5 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 29.8143 | 1 | 3 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 1.2589 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 62.1451 | 2 | 7 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 7.9433 | 1 | 1 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 8.2400 | 1 | 2 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 16.0546 | 1 | 2 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 26.2762 | 1 | 4 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 17.3851 | 1 | 3 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 12.0392 | 2 | 6 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 15.0752 | 1 | 3 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 14.1171 | 1 | 3 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.5193 | 1 | 3 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 89.1251 | 1 | 1 |
| endonuclease IV | Escherichia coli | Potency | 12.0627 | 1 | 2 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 18.4390 | 10 | 19 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 15.4803 | 1 | 1 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 18.2906 | 4 | 4 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 24.5353 | 1 | 5 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 0.4686 | 1 | 1 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 0.0042 | 1 | 1 |
| G | Vesicular stomatitis virus | Potency | 16.0546 | 1 | 2 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 12.0392 | 1 | 3 |
| geminin | Homo sapiens (human) | Potency | 2.0250 | 2 | 6 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 6.7491 | 2 | 3 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 1.3777 | 2 | 3 |
| GLS protein | Homo sapiens (human) | Potency | 16.0825 | 2 | 2 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 0.0355 | 1 | 1 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 17.0534 | 4 | 8 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 7.4978 | 1 | 1 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 29.0929 | 1 | 1 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 8.2400 | 1 | 6 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 16.0546 | 1 | 2 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 0.0100 | 2 | 2 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 77.4924 | 2 | 2 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 16.0546 | 1 | 4 |
| Interferon beta | Homo sapiens (human) | Potency | 16.0546 | 1 | 2 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 8.9295 | 1 | 7 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 30.1230 | 2 | 2 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 5.0119 | 1 | 1 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 6.3446 | 2 | 2 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 11.0758 | 1 | 3 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 14.3986 | 2 | 6 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 5.0119 | 1 | 1 |
| Nrf2 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 0.8769 | 3 | 3 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 14.5810 | 1 | 1 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 6.0070 | 1 | 1 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 8.4504 | 3 | 4 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 1.9953 | 1 | 1 |
| Parkin | Homo sapiens (human) | Potency | 16.3601 | 1 | 1 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 8.4921 | 1 | 1 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 13.2170 | 1 | 2 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 3.6225 | 1 | 1 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 2.6601 | 1 | 1 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 39.8107 | 1 | 1 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 14.4229 | 1 | 3 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 29.8493 | 1 | 1 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 25.1189 | 2 | 2 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 4.0569 | 2 | 5 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 11.6230 | 1 | 6 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 13.5037 | 3 | 3 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 46.4662 | 2 | 4 |
| snurportin-1 | Homo sapiens (human) | Potency | 77.4924 | 2 | 2 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 30.9584 | 1 | 5 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 3.1623 | 1 | 1 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 32.0272 | 1 | 3 |
| TDP1 protein | Homo sapiens (human) | Potency | 17.6918 | 2 | 11 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 6.0585 | 2 | 7 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 17.3372 | 3 | 5 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 15.8365 | 2 | 3 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 44.9647 | 2 | 2 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 1.4926 | 2 | 2 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 37.6460 | 1 | 2 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 7.4978 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 1.8870 | 1 | 3 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 0.0594 | 4 | 4 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.6622 | 3 | 6 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 1.8870 | 1 | 3 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Ki | 6.3000 | 1 | 2 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 0.6830 | 3 | 5 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | Ki | 0.1000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | Ki | 0.1000 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 20.8750 | 5 | 11 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Ki | 20.8750 | 5 | 11 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 54.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Ki | 20.8750 | 5 | 11 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 0.1800 | 1 | 1 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 0.1800 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.1800 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.0029 | 1 | 1 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0048 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.0300 | 1 | 1 |
| Androgen receptor | Homo sapiens (human) | IC50 | 0.0650 | 1 | 1 |
| Androgen receptor | Rattus norvegicus (Norway rat) | Ki | 0.0110 | 1 | 1 |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | Ki | 0.0240 | 1 | 4 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 6 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 0.0035 | 1 | 3 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 0.0023 | 4 | 6 |
| Beta-1 adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.1379 | 5 | 5 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | IC50 | 0.0005 | 1 | 3 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | Ki | 0.0003 | 3 | 5 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | IC50 | 0.2933 | 1 | 3 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | Ki | 0.2200 | 1 | 3 |
| Beta-carbonic anhydrase 1 | Mycobacterium tuberculosis H37Rv | Ki | 0.8553 | 3 | 10 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 268.5300 | 3 | 10 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 6 |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.0230 | 1 | 1 |
| Carbonic anhydrase | Candida albicans SC5314 | Ki | 1.2977 | 5 | 19 |
| Carbonic anhydrase | Helicobacter pylori 26695 | Ki | 1.2769 | 2 | 8 |
| Carbonic anhydrase | Methanosarcina thermophila | Ki | 0.5667 | 2 | 6 |
| Carbonic anhydrase | Methanothermobacter thermautotrophicus str. Delta H | Ki | 47.0167 | 1 | 3 |
| Carbonic anhydrase | Saccharomyces cerevisiae S288C | Ki | 3.2851 | 2 | 5 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 0.1165 | 1 | 4 |
| Carbonic anhydrase | Anopheles gambiae (African malaria mosquito) | Ki | 0.2804 | 1 | 4 |
| Carbonic anhydrase | Astrosclera willeyana | Ki | 0.2518 | 1 | 4 |
| Carbonic anhydrase | Cryptococcus neoformans var. grubii | Ki | 2.1854 | 2 | 5 |
| Carbonic anhydrase | Mycobacterium tuberculosis H37Rv | Ki | 0.1690 | 1 | 2 |
| Carbonic anhydrase | Nakaseomyces glabratus CBS 138 | Ki | 3.5555 | 1 | 4 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 0.1342 | 2 | 8 |
| Carbonic anhydrase | Sulfurihydrogenibium sp. YO3AOP1 | Ki | 0.0095 | 1 | 4 |
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 | 10.4967 | 4 | 5 |
| Carbonic anhydrase 1 | Homo sapiens (human) | Ki | 109,657,033.9327 | 143 | 456 |
| Carbonic anhydrase 12 | Homo sapiens (human) | Ki | 13.6507 | 46 | 150 |
| Carbonic anhydrase 13 | Homo sapiens (human) | Ki | 46.5006 | 3 | 15 |
| Carbonic anhydrase 13 | Mus musculus (house mouse) | Ki | 22.6998 | 13 | 55 |
| Carbonic anhydrase 14 | Homo sapiens (human) | Ki | 22.6657 | 19 | 86 |
| Carbonic anhydrase 15 | Mus musculus (house mouse) | Ki | 0.0597 | 4 | 14 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 | 0.0168 | 14 | 24 |
| Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 808.3846 | 162 | 527 |
| Carbonic anhydrase 2 | Mycobacterium tuberculosis H37Rv | Ki | 0.5658 | 1 | 4 |
| Carbonic anhydrase 3 | Bos taurus (cattle) | Ki | 4.7406 | 2 | 5 |
| Carbonic anhydrase 3 | Homo sapiens (human) | Ki | 288.4336 | 12 | 47 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | IC50 | 0.2677 | 2 | 3 |
| Carbonic anhydrase 4 | Homo sapiens (human) | IC50 | 0.0288 | 3 | 6 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | Ki | 1,143,025.4650 | 24 | 79 |
| Carbonic anhydrase 4 | Homo sapiens (human) | Ki | 26.2955 | 20 | 80 |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | Ki | 22.6603 | 16 | 86 |
| Carbonic anhydrase 5A, mitochondrial | Mus musculus (house mouse) | Ki | 3.5033 | 1 | 15 |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | Ki | 22.6230 | 16 | 86 |
| Carbonic anhydrase 6 | Homo sapiens (human) | Ki | 28.3961 | 17 | 68 |
| Carbonic anhydrase 7 | Homo sapiens (human) | Ki | 22.3483 | 21 | 87 |
| Carbonic anhydrase 9 | Homo sapiens (human) | IC50 | 0.0258 | 3 | 4 |
| Carbonic anhydrase 9 | Homo sapiens (human) | Ki | 8.5033 | 81 | 270 |
| Carbonic anhydrase, alpha family | Hydrogenovibrio crunogenus XCL-2 | Ki | 0.0100 | 1 | 4 |
| Chain A, Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 0.0069 | 1 | 20 |
| Chain A, CARBONIC ANHYDRASE II | Homo sapiens (human) | Ki | 0.0006 | 1 | 5 |
| Chain A, CARBONIC ANHYDRASE IV | Mus musculus (house mouse) | IC50 | 0.0453 | 1 | 1 |
| Cytochrome P450 2A13 | Homo sapiens (human) | Ki | 1.4000 | 1 | 1 |
| Cytochrome P450 2A6 | Homo sapiens (human) | Ki | 3.0000 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | Ki | 0.0360 | 1 | 2 |
| Cytochrome P450 2C9 | Homo sapiens (human) | Ki | 0.0420 | 1 | 2 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 11.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 0.0390 | 2 | 4 |
| Delta carbonic anhydrase | Conticribra weissflogii | Ki | 0.1777 | 1 | 4 |
| Delta-type opioid receptor | Mus musculus (house mouse) | Ki | 12.0354 | 2 | 8 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0120 | 2 | 5 |
| Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | Ki | 0.1850 | 1 | 2 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0145 | 1 | 4 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 24.0563 | 1 | 4 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 123.1667 | 1 | 6 |
| Muscarinic acetylcholine receptor DM1 | Drosophila melanogaster (fruit fly) | Ki | 2.8900 | 2 | 2 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 | 3.0267 | 3 | 6 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 7.2751 | 2 | 2 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Ki | 3.6700 | 1 | 1 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 | 3.8400 | 2 | 2 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 12.0226 | 1 | 1 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | Ki | 3.6700 | 1 | 1 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 | 3.8400 | 2 | 2 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | Ki | 3.6700 | 1 | 1 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 | 3.8400 | 2 | 2 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | Ki | 3.6700 | 1 | 1 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 | 3.8400 | 2 | 2 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 10.2329 | 1 | 1 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | Ki | 3.6700 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-7 | Rattus norvegicus (Norway rat) | Ki | 0.0250 | 1 | 1 |
| Prolyl endopeptidase | Rattus norvegicus (Norway rat) | Ki | 0.3275 | 1 | 2 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 0.7730 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.3250 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 4.8980 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 2.6020 | 1 | 1 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | Ki | 7.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 2A1 | Homo sapiens (human) | Ki | 5.0745 | 1 | 2 |
| Translocator protein | Rattus norvegicus (Norway rat) | Ki | 0.8400 | 1 | 1 |